Sandoz Group AG

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sandoz Group AG engages in focusing on generic pharmaceuticals and bio similar medical products. It acquires, manages and sells investments and intellectual property in the healthcare and medical device industry and conducts all business at home and abroad. The firm can acquire, sell, debit and manage interests in other companies, intellectual property rights and real estate at home and abroad, as well as establish branches and subsidiaries at home and abroad. The company was founded on January 17, 2022 and is headquartered in Rotkreuz, Switzerland.

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Mathai Mammen and Michael Rechsteiner nominated to stand for election to Sandoz Board of Directors at upcoming Annual General Meeting Remco Steenbergen appointed as Sandoz CFO and member of Executive Committee as of July 1, 2024, and consequently not standing for re-election to Board of Directors Colin Bond to retire as CFO of Sandoz on June 30, 2024 Basel, March 5, 2024 - The Board of Directors of Sandoz announced today that it proposes Mathai Mammen, M.D.

Sandoz announces nominations to the Board of Directors and leadership change

MEDIA RELEASE CIMERLI®*, a ranibizumab biosimilar, is interchangeable with LUCENTIS®** (ranibizumab injection) for all approved indications Dedicated retina sales and field reimbursement team integrated into Sandoz, ensuring seamless experience for providers and patients Basel, March 4, 2024 – Sandoz, the global leader in generic and biosimilar medicines, has completed the acquisition of the US biosimilar CIMERLI®* (ranibizumab-eqrn) from Coherus BioSciences, Inc, ahead of anticipated timelines. The acquisition builds on the leading Sandoz ophthalmic platform in the US and lays an even stronger foundation for future product launches.

Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US market

Swiss generic and biosimilar manufacturer Sandoz on Thursday said it had entered into a $265 million settlement agreement in a price-fixing case in the United States.

Sandoz enters $265 mln settlement agreement in U.S. price-fixing case

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules  MEDIA RELEASE Sandoz US to pay USD 265 million in exchange for full release of all claims by the class Resolves all federal antitrust damages for direct purchaser class plaintiffs' claims in this litigation, if approved by Court Basel, February 29, 2024 – Sandoz Inc. and its subsidiary Fougera Pharmaceuticals Inc. (together, “Sandoz US”) – both indirect subsidiaries of Sandoz Group AG – have entered into a settlement agreement with the class of direct purchaser plaintiffs in the multidistrict litigation entitled In re Generic Pharmaceuticals Pricing Antitrust Litigation in the US District Court for the Eastern District of Pennsylvania.

Sandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser class plaintiffs

BENGALURU, India, Feb. 8, 2024 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced a five-year partnership with Sandoz AG ('Sandoz') which provides Sandoz the exclusive rights to promote, sell and distribute biosimilar Trastuzumab (market value of AUD$35 million1) and biosimilar Bevacizumab (market value of AUD$45 million2) in Australia.  Under the agreement, Sandoz will distribute the Biocon Biologics' brands, OGIVRI® (bTrastuzumab) and ABEVMY® (bBevacizumab), and facilitate the sustained access of these medications that were previously distributed by another pharmaceutical company to patients in Australia.

Biocon Biologics Partners with Sandoz Australia for Biosimilars Trastuzumab and Bevacizumab

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Graeme Pitkethly nominated as candidate for election to the Sandoz Board of Directors at the upcoming Annual General Meeting François-Xavier Roger announced to pursue a new executive responsibility and therefore to step down from the Sandoz Board of Directors post publication of the financial statements 2023 Basel, February 1, 2024 - The Board of Directors of Sandoz announced today that it proposes Graeme Pitkethly for election to its Board of Directors at the company's next Annual General Meeting on April 30, 2024.

Sandoz announces changes in the Board of Directors

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE             Tyruko® approved for all indications of reference medicine             Tyruko® biosimilar to treat adults with highly active relapsing remitting multiple sclerosis (RRMS)             Launch strengthens well-established Sandoz biosimilar portfolio in Europe Basel, January 31, 2024 – Sandoz, the global leader in generic and biosimilar medicines, today announces the launch of Tyruko® (natalizumab) in Germany from February 1.

Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany

Sandoz on Monday announced a deal to buy Cimerli, a biosimilar drug to treat vision impairment and loss, from Coherus BioSciences Inc. for $170 million.

Sandoz to buy eye drug Cimerli in $170 million deal

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE CIMERLI®*, a ranibizumab biosimilar, is interchangeable with LUCENTIS®** (ranibizumab-injection) for all approved indications Acquisition strengthens Sandoz ophthalmology portfolio Basel, January 22, 2024 – Sandoz, the global leader in generic and biosimilar medicines, has signed an agreement to acquire the US biosimilar ranibizumab CIMERLI®* (ranibizumab-eqrn) from Coherus BioSciences, Inc. for an upfront cash purchase payment of USD 170 million.

Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US market

Aspen Pharmacare will buy the Chinese business of Swiss group Sandoz , including commercialisation rights and intellectual property for some established products and those in the pipeline, for up to 92.6 million euros ($100.6 million), the South African company said on Monday.

South Africa's Aspen Pharmacare to buy Sandoz's China business

Basel, November 21, 2023 – Sandoz, the global leader in generic and biosimilar medicines, today announces the launch of Hyrimoz® (adalimumab) citrate-free high concentration formulation (HCF; 100 mg/mL) in Europe. The medicine will become available to patients progressively across European markets, starting today.

Sandoz launches Hyrimoz® (adalimumab) high-concentration formulation in Europe, aiming to improve patient care

Sandoz is a global leader in the generics and biosimilars sector, with a strong position in the off-patent medicines market. The company recently listed and plans to aggressively pursue a slice of the $208 billion (and increasing) global off-patent medicines market. Sandoz expects its EBITDA margin to increase from 18-19% in 2023 to 24-26% by 2028, driving significant improvements in profitability.

Sandoz Group: Novartis Spinoff With A Double-Digit EBITDA CAGR Through 2028

Basel, November 10, 2023 – Sandoz, the global leader in generic and biosimilar medicines, has opened two new European facilities, in line with its ongoing plans to strengthen sustainable development and supply of critical medicines in Europe and beyond.

Sandoz inaugurates new antibiotic production plant in Austria and new biosimilar development center in Germany

NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN  Inaugural Eurobonds priced earlier today; three tranches of EUR 700 million, EUR 700 million and EUR 600 million Maturities of 3.5, 6.5 and 10 years, carrying fixed coupons at 3.97%, 4.22% and 4.50%, respectively Proceeds to repay bridge loan facility and for general corporate purposes Basel, November 8, 2023 – Sandoz, the global leader in generic and biosimilar medicines, today announced the issuance of three highly successful inaugural Eurobonds, with total gross proceeds of EUR 2.0 billion. Following a debut transaction in CHF last month, this issuance marks the entry of Sandoz into the EUR debt capital market.

Sandoz successfully issues EUR 2.0 billion inaugural Eurobonds

Basel, October 26, 2023 – Sandoz, the global leader in generic and biosimilar medicines, today announced the issuance of two highly successful inaugural CHF bonds with gross proceeds of CHF 750 million.

Sandoz successfully issues CHF 750 million in inaugural bonds

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Nine-month net sales1 of USD 7.1 billion, up 6 percent in constant currencies (cc)(1) Solid performance in Generics; Biosimilars grow double-digits Recent strategic milestones include US Hyrimoz® launch, approval of Tyruko® in US and Europe, partnership on ustekinumab and closing of Mycamine® acquisition Full-year 2023 guidance confirmed Sandoz successfully listed on SIX Swiss Exchange as independent company on October 4 Basel, October 24, 2023 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced its year-to-date sales for the first nine months of 2023, with net sales up 6 percent in constant currencies (cc) to reach USD 7.1 billion.

Sandoz reports year-to-date sales for the first nine months of 2023

Novartis

Ad hoc announcement pursuant to Art. 53 LR Transformation into a “pure-play” innovative medicines business is complete, with the spin-off of Sandoz; commentary below is on continuing operations 2 Q 3 sales grew +12% (cc, +12% USD) with core operating income growing +21% (cc, +17% USD) Growth driven by continued strong performance from Kesimpta (+124% cc), Entresto (+31% cc), Kisqali (+76% cc), Pluvicto (+217% cc) and Scemblix (+157% cc) Q3 operating income grew +13% (cc, -4% USD) driven by higher sales and lower restructuring charges, partly offset by higher impairments through discontinuation of early stage development projects Q3 net income grew +37% (cc, +14% USD) mainly due to higher operating income Q3 free cash flow 3 was USD 5.0 billion (+24% USD) driven by higher net cash flows from operating activities Q3 core EPS grew +29% (cc, +24% USD) to USD 1.74 Strong nine months performance with sales growing +10% (cc, +8% USD) and core operating income growing +19% (cc, +13% USD) Q3 key innovation milestones, including positive Ph3 data for multiple pipeline assets with blockbuster potential: Cosentyx – FDA approval for intravenous formulation in three indications (PsA, AS, nr-axSpA)

Novartis delivers 12% sales and 21% core operating income growth from continuing operations (in cc¹). Executes Sandoz spin-off, achieves important innovation milestones, and raises FY 2023 guidance

Ex-Sandoz, Novartis confirmed its yearly guidance and capital allocation priority (DPS growth and buyback). We believe NVS might experience a margin uplift following the spin-off. Sandoz started trading with a market cap of $11.2 billion. The company has now completed its business transformation. We expect positive pipeline readouts; however, Novartis's valuation looks full.

Novartis: Better Margin Visibility Ex-Sandoz

Swiss drug giant Novartis AG (ADR) (NYSE:NVS) has just completed the spin-off of Sandoz, its generics and biosimilars business. Kelloggs has done the same, hiving off its cereal business into WK Kellogg Co this week, and renaming the remaining snacks and frozen food business Kellanova.

Spin-outs on the rise as companies try to win out in desolate M&A market

Sandoz (OTCMKT: SDZNY ) stock is a hot topic among traders on Wednesday as the company starts trading after a spinoff. Let's get into everything investors need to know about Sandoz below!

SDZNY Stock: 7 Things to Know as Novartis Spinoff Sandoz Starts Trading Today

Swiss drugs giant Novartis AG has completed the spin-off of its generics business Sandoz, which made an underpowered stock market debut. From an IPO price of 24 Swiss Francs, the stock drifted down to 23.82 Swiss Francs.

Novartis spin-off completed as Sandoz makes subdued start on Swiss bourse

Novartis has completed the planned spin-off of its generics and biosimilars business, Sandoz, which will begin trading on the SIX Swiss Exchange on Wednesday.

Novartis unit Sandoz set to start trading after completing spinoff

Novartis has completed the planned spin-off of its generics and biosimilars business Sandoz , the Swiss drugmaker said in a statement on Wednesday.

Novartis completes Sandoz spinoff

Basel, October 4, 2023 – Sandoz, the global leader in generic and biosimilar medicines, today celebrates the start of share trading on the SIX Swiss Exchange as an independent company.

Sandoz enters new era as standalone global leader and European champion in generic and biosimilar medicines

Ad hoc announcement pursuant to Art. 53 LR  Novartis executes separation of the Sandoz business to create an independent company by way of a 100% Spin-off Shares of Sandoz will be listed and commence trading today on the SIX Swiss Exchange Spin-off allows shareholders to benefit from a Novartis with capital and management attention fully focused on innovative medicines Novartis pipeline one of the industry's most competitive, focused on key next-generation platforms and four core therapeutic areas Company reiterates guidance for FY 2023, with sales expected to grow high single digits and core operating income low double digits to mid-teens 1 Novartis to maintain consistent approach to capital allocation priorities including share buy-back and continued strong and growing dividend policy, with no re-basing after the Sandoz Spin-off Basel, October 4, 2023 — Novartis today completed the Spin-off of Sandoz, its Generics and Biosimilars business, through a dividend-in-kind distribution to holders of Novartis shares and American Depositary Receipts (ADRs), with each holder receiving one Sandoz share for every five Novartis shares or one Sandoz ADR for every five Novartis ADRs, held at the close of business on October 3, 2023.

News for Sandoz Group AG Stock (SDZNY)